The QuicDNA Max programme is a platform-based, prospective, multi-centre, exploratory diagnostic study conducted across clinical trials

QuicDNA Max Research Programme – multi site, multi-centre, non-interventional, biomarker platform study. Assessing blood based ctDNA (circulating tumour) testing to guide cancer care across multiple cancer types

The QuicDNA Max study is exploring a new blood test (liquid biopsy) for people with advanced cancer. It aims to see if this test, which looks for cancer DNA in the blood, can help doctors make better treatment decisions and track cancer changes, offering a simpler alternative to traditional biopsies.